Physician profile
Debra Goodman
NPI 1013325810
$2,158.96
in general payments reported to CMS, 2019-2025
22 companies · $860 in 2025
The $860 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $42.91 · 2023: $457 · 2024: $800 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,090 · Education: $25.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,090.38 |
| Education | $25.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $463.26 | 2023-2025 | |
| Madrigal Pharmaceuticals | $252.02 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $244.04 | 2024-2025 | Epclusa |
| Ferring Pharmaceuticals INC. | $178.20 | 2023-2024 | Rebyota |
| Phathom Pharmaceuticals, INC. | $153.43 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $143.54 | 2023-2025 | Omvoh, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $120.23 | 2023 | Zeposia |
| Mallinckrodt Hospital Products INC. | $106.03 | 2024-2025 | Terlivaz |
| Celltrion USA INC. | $85.17 | 2024-2025 | Vegzelma, Zymfentra |
| Ipsen Biopharmaceuticals, INC | $67.65 | 2025 | Iqirvo |
| Genzyme Corporation | $52.82 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $51.59 | 2024-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.87 | 2024-2025 | Xifaxan |
| Novo Nordisk INC | $31.95 | 2025 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $24.62 | 2025 | Entyvio |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $23.75 | 2022 | |
| Ardelyx, INC. | $21.17 | 2024 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $19.98 | 2023 | Andexxa |
| Merck Sharp & Dohme LLC | $19.16 | 2022 | |
| Intercept Pharmaceuticals, INC. | $19.12 | 2023 | Ocaliva |
| Janssen Biotech, INC. | $16.44 | 2023 | Stelara |
| Celgene Corporation | $15.92 | 2024 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.